GeoVax Advances Mpox Vaccine Development Amid Rising Global Cases

GeoVax Labs, Inc. is making significant strides in the development of its GEO-MVA vaccine for Mpox and smallpox, addressing the urgent need for diverse vaccine options amid rising global cases. The European Medicines Agency (EMA) has provided favorable feedback, setting the vaccine on an expedited path toward market access. This development is critical as Mpox cases increase across the U.S., Europe, and Africa, highlighting the need for additional vaccine supplies.

David Dodd, Chairman and CEO of GeoVax, emphasized the importance of diversifying stockpile planning to ensure public health security worldwide. The company's innovative production process aims to enhance vaccine availability and reduce costs, offering a promising solution to the current limited supply of MVA-based vaccines.

GeoVax's progress is further supported by its proposal under the BARDA Rapid Response Partnership Vehicle (RRPV), which seeks to fund scalable vaccine platforms. This initiative could eliminate dependencies on single-source vaccine options, providing a more resilient defense against high-consequence threats like smallpox.

The expedited regulatory pathway and the potential for scalable production underscore the significance of GeoVax's efforts in combating infectious diseases. With the GEO-MVA vaccine, GeoVax is poised to contribute to global health security, offering a complementary or alternative solution to existing vaccine options.